Citation: Zhaoyong Kang, Shen Li, Yan Li, Jingfeng Song, Yangrui Peng, Yihua Chen. Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024)[J]. Chinese Chemical Letters, ;2025, 36(7): 110447. doi: 10.1016/j.cclet.2024.110447 shu

Small molecular inhibitors and degraders targeting STAT3 for cancer therapy: An updated review (from 2022 to 2024)

Zhaoyong Kang ^{a, b, 1} ,
Shen Li ^{b, 1} ,
Yan Li ^c ,
Jingfeng Song ^a ,
Yangrui Peng ^b ,
Yihua Chen ^{a, b, *,}

a.
School of Pharmaceutical Sciences and Yunnan Key Laboratory of Pharmacology for Natural Products and Yunnan College of Modern Biomedical Industry, Kunming Medical University, Kunming 650500, China
b.
Shanghai Frontiers Science Center of Genome Editing and Cell Therapy, Shanghai Key Laboratory of Regulatory Biology, The Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China
c.
Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, School of Chemistry and Molecular Engineering, East China Normal University, Shanghai 200062, China

Received Date: 15 July 2024
Revised Date: 9 September 2024
Accepted Date: 11 September 2024
Available Online: 11 September 2024

Figures(9)

Signal transducer and activator of transcription 3 (STAT3) is a member of the transcription factors involved in regulating many physiological and pathological processes, such as cell proliferation, angiogenesis and immune escape. STAT3 has been identified as a potential therapeutic target for various cancers. Although numerous STAT3 inhibitors have been discovered and optimized to directly inhibit STAT3 activity, they are not yet authorized for clinical use and only a few have entered clinical trials. Furthermore, several proteolysis-targeting chimera (PROTAC) molecules with STAT3 degrading effects have been developed. The event-driven action of PROTAC overcome the drawbacks of STAT3, a traditional undruggable target, and addressed possible resistance to small-molecule inhibitors by degrading the entire STAT3 protein. In this review, we presented a brief introduction to STAT3 and its functions in various cancers, and systematically overviewed the pharmacological effects of inhibitors targeting different domains of STAT3 in the last three years, the structural characterization of the main scaffold, the design strategies, and the pharmacological activities of the substituents. Also, the binding patterns and interactions of some inhibitors with STAT3 were analyzed in detail and the recent advances in STAT3 degraders are also summarized. We anticipate that this perspective will contribute to the design and optimize more novel effective and specific STAT3 inhibitors or degraders for carcinoma treatment.
- STAT3,
- Small molecule inhibitors,
- Cancer therapy,
- STAT3 degraders,
- PROTAC
1. [1]
  Y. Li, C. Zhang, A. Martincuks, A. Herrmann, H. Yu, Nat. Rev. Cancer 23 (2023) 115–134. doi: 10.1038/s41568-022-00537-3
2. [2]
  H. Wang, Q. Man, F. Huo, et al., MedComm 3 (2022) e124. doi: 10.1002/mco2.124
3. [3]
  Y. Liu, S. Liao, S. Bennett, et al., Cell Prolif. 54 (2021) e12974. doi: 10.1111/cpr.12974
4. [4]
  W. Lin, Y. Chang, M. Hong, et al., Oncogene 40 (2021) 791–805. doi: 10.1038/s41388-020-01566-8
5. [5]
  D.E. Johnson, R.A. O'Keefe, J.R. Grandis, Nat. Rev. Clin. Oncol. 15 (2018) 234–248. doi: 10.1038/nrclinonc.2018.8
6. [6]
  H. Lee, A.J. Jeong, S.K. Ye, BMB Rep. 52 (2019) 415–423. doi: 10.5483/bmbrep.2019.52.7.152
7. [7]
  Q. Huang, Y. Zhong, H. Dong, et al., Eur. J. Med. Chem. 187 (2020) 111922. doi: 10.1016/j.ejmech.2019.111922
8. [8]
  D. Zhao, J. Zhang, L. Zhang, et al., Acta Pharm. Sin. B 13 (2023) 694–708.
9. [9]
  P.S. Thilakasiri, R.S. Dmello, T.L. Nero, et al., Semin. Cancer Biol. 68 (2021) 31–46. doi: 10.1016/j.semcancer.2019.09.022
10. [10]
  M. Jiang, B. Li, Cells 11 (2022) 3131. doi: 10.3390/cells11193131
11. [11]
  J. Qin, L. Yan, J. Zhang, W. Zhang, J. Exp. Clin. Cancer Res. 38 (2019) 195. doi: 10.1186/s13046-019-1206-z
12. [12]
  D. Liu, H. Ge, F. Xu, et al., Chin. Chem. Lett. 33 (2022) 2969–2974.
13. [13]
  J. Dong, X. Cheng, W. Zhang, J. Qin, J. Med. Chem. 64 (2021) 8884–8915. doi: 10.1021/acs.jmedchem.1c00629
14. [14]
  Z. Wang, C. Hui, Y. Xie, Bioorg. Chem. 115 (2021) 105169. doi: 10.1016/j.bioorg.2021.105169
15. [15]
  S.M. Zarezadeh, A.M. Sharafi, G. Erabi, et al., Recent Pat. Anticancer Drug Discov. 19 (2024) 403–502. doi: 10.2174/1574892818666230803100554
16. [16]
  J. Qin, X. Shen, J. Zhang, D. Jia, Eur. J. Med. Chem. 190 (2020) 112122.
17. [17]
  L. Xu, X. Mu, M. Liu, et al., Chin. Chem. Lett. 34 (2023) 108063.
18. [18]
  X. Yang, L. Xu, L. Yang, S. Xu, Bioorg. Med. Chem. 91 (2023) 117382. doi: 10.1016/j.bmc.2023.117382
19. [19]
  B. Debnath, S. Xu, N. Neamati, J. Med. Chem. 55 (2012) 6645–6668. doi: 10.1021/jm300207s
20. [20]
  A. Gelain, M. Mori, F. Meneghetti, S. Villa, Curr. Med. Chem. 26 (2019) 5165–5206. doi: 10.2174/0929867325666180719122729
21. [21]
  J. Song, J. Wang, S. Tian, H. Li, Curr. Med. Chem. 30 (2023) 1824–1847. doi: 10.2174/0929867329666220819093117
22. [22]
  J. Yang, L. Wang, X. Guan, J.J. Qin, Pharmacol. Res. 182 (2022) 106357. doi: 10.1016/j.phrs.2022.106357
23. [23]
  C.D. Mohan, S. Rangappa, H.D. Preetham, et al., Semin. Cancer Biol. 80 (2022) 157–182. doi: 10.1016/j.semcancer.2020.03.016
24. [24]
  F. Laudisi, F. Cherubini, G. Monteleone, C. Stolfi, Int. J. Mol. Sci. 19 (2018) 1787. doi: 10.3390/ijms19061787
25. [25]
  D. Resetca, S. Haftchenary, P.T. Gunning, D.J. Wilson, J. Biol. Chem. 289 (2014) 32538–32547.
26. [26]
  J. Huynh, A. Chand, D. Gough, M. Ernst, Nat. Rev. Cancer 19 (2019) 82–96. doi: 10.1038/s41568-018-0090-8
27. [27]
  M. Rincon, F.V. Pereira, Int. J. Mol. Sci. 19 (2018) 1656. doi: 10.3390/ijms19061656
28. [28]
  R. Yang, M. Rincon, Int. J. Biol. Sci. 12 (2016) 532–544. doi: 10.7150/ijbs.15153
29. [29]
  J. Wegrzyn, R. Potla, Y.J. Chwae, et al., Science 323 (2009) 793–797. doi: 10.1126/science.1164551
30. [30]
  H. Chen, A. Bian, W. Zhou, et al., ACS Cent. Sci. 10 (2024) 579–594. doi: 10.1021/acscentsci.3c01440
31. [31]
  Z. Wen, Z. Zhong, J.E. Darnell, Jr., Cell 82 (1995) 241–250.
32. [32]
  D.J. Gough, A. Corlett, K. Schlessinger, et al., Science 324 (2009) 1713–1716. doi: 10.1126/science.1171721
33. [33]
  D.J. Gough, L. Koetz, D.E. Levy, PLoS One 8 (2013) e83395. doi: 10.1371/journal.pone.0083395
34. [34]
  D.J. Gough, I.J. Marié, C. Lobry, I. Aifantis, D.E. Levy, Blood 124 (2014) 2252–2261. doi: 10.1182/blood-2013-02-484196
35. [35]
  M. Rammohan, R.S. Bhansali, Y.C. Tsai, et al., Blood 132 (2018) 3898. doi: 10.1182/blood-2018-99-115429
36. [36]
  L. Zhao, X. Xiong, L. Liu, et al., Chin. Chem. Lett. 33 (2022) 1841–1849. doi: 10.3390/biology11121841
37. [37]
  Y. Yang, X. Fan, Y. Liu, et al., Biochem. Pharmacol. 212 (2023) 115521.
38. [38]
  A. Tesoriere, A. Dinarello, F. Argenton, Biomedicines 9 (2021) 956. doi: 10.3390/biomedicines9080956
39. [39]
  Y. Belo, Z. Mielko, H. Nudelman, et al., Biochim. Biophys. Acta Gen. Subj. 1863 (2019) 1343–1350.
40. [40]
  A. Xiong, Z. Yang, Y. Shen, J. Zhou, Q. Shen, Cancers 6 (2014) 926–957. doi: 10.3390/cancers6020926
41. [41]
  C.L. Yu, D.J. Meyer, G.S. Campbell, et al., Science 269 (1995) 81–83. doi: 10.1126/science.7541555
42. [42]
  J. Weng, S. Gu, X. Wan, et al., Cell Res. 18 (2008) 1199–1209. doi: 10.1038/cr.2008.307
43. [43]
  M.S. Redell, M.J. Ruiz, T.A. Alonzo, R.B. Gerbing, D.J. Tweardy, Blood 117 (2011) 5701–5709. doi: 10.1182/blood-2010-04-280123
44. [44]
  P. Yue, J. Turkson, Expert Opin. Investig. Drugs 18 (2009) 45–56. doi: 10.1517/13543780802565791
45. [45]
  V.G. Deepak Roshan, M.S. Sinto, S. Thomas, S. Kannan, J. Cancer Res. Ther. 14 (2018) 403–408. doi: 10.4103/0973-1482.188295
46. [46]
  J.I. Song, J.R. Grandis, Oncogene 19 (2000) 2489–2495. doi: 10.1038/sj.onc.1203483
47. [47]
  J.M. Adams, S. Cory, Oncogene 26 (2007) 1324–1337. doi: 10.1038/sj.onc.1210220
48. [48]
  Y. You, K. Zhu, J. Wang, et al., Chin. Chem. Lett. 34 (2023) 108336.
49. [49]
  M. Watanabe, T. Sato, A. Umetsu, et al., Biomedicines 12 (2024) 1165. doi: 10.3390/biomedicines12061165
50. [50]
  S. Zou, Q. Tong, B. Liu, et al., Mol. Cancer 19 (2020) 145. doi: 10.1109/iccia49625.2020.00035
51. [51]
  B. Chaudhary, E. Elkord, Vaccines 4 (2016) 28. doi: 10.3390/vaccines4030028
52. [52]
  Y. Zhang, Y. Wei, S. Jiang, et al., Phytomedicine 99 (2022) 153939.
53. [53]
  J.B. Lamano, J.B. Lamano, Y.D. Li, et al., Clin. Cancer Res. 25 (2019) 3643–3657. doi: 10.1158/1078-0432.ccr-18-2402
54. [54]
  Q. Chen, S. Zhuang, Y. Hong, et al., Oncogene 41 (2022) 1421–1433. doi: 10.1038/s41388-021-02173-x
55. [55]
  T. Qian, J. Hong, L. Wang, et al., Mol. Immunol. 111 (2019) 162–171.
56. [56]
  E.J. Hillmer, H. Zhang, H.S. Li, S.S. Watowich, Cytokine Growth Factor Rev. 31 (2016) 1–15. doi: 10.1016/j.cytogfr.2016.05.001
57. [57]
  Y. Wang, Y. Shen, S. Wang, Q. Shen, X. Zhou, Cancer Lett. 415 (2018) 117–128. doi: 10.1117/12.2290215
58. [58]
  F. Luo, M. Luo, Q.X. Rong, et al., J. Immunother. Cancer 7 (2019) 245.
59. [59]
  L. Tong, J. Li, Q. Li, et al., Theranostics 10 (2020) 5943–5956. doi: 10.7150/thno.41498
60. [60]
  L. Fu, Z. Su, S. Wu, et al., Chin. Chem. Lett. (2024), 110227. doi: 10.1016/j.cclet.2024.110227
61. [61]
  P. Guha, J. Gardell, J. Darpolor, et al., Oncogene 38 (2019) 533–548. doi: 10.1038/s41388-018-0449-z
62. [62]
  R. Sun, Y. Sun, C. Wu, et al., Mol. Ther. 31 (2023) 3193–3209.
63. [63]
  N. Chuangchot, P. Jamjuntra, S. Yangngam, et al., Breast Cancer Res. 25 (2023) 86. doi: 10.1186/s13058-023-01684-7
64. [64]
  B. Chen, L. Gong, J. Feng, et al., Chin. Chem. Lett. 35 (2024) 109432.
65. [65]
  Q. Zeng, Z. Liu, T. Niu, et al., Chin. Chem. Lett. 34 (2023) 107747.
66. [66]
  W.Z. Li, H.Z. Xi, Y.J. Wang, et al., Chem. Biol. Drug Des. 98 (2021) 835–849. doi: 10.1111/cbdd.13939
67. [67]
  Y. Wang, H. Liu, W. Li, et al., Eur. J. Med. Chem. 246 (2023) 114953.
68. [68]
  Q. Huang, Y. Zhong, B. Li, et al., Eur. J. Med. Chem. 221 (2021) 113525.
69. [69]
  Y. Zhong, L. Deng, S. Shi, et al., Acta Pharmacol. Sin. 43 (2022) 1013–1023. doi: 10.1038/s41401-021-00718-0
70. [70]
  L. Deng, J. Mo, Y. Zhang, et al., J. Med. Chem. 65 (2022) 13094–13111. doi: 10.1021/acs.jmedchem.2c00940
71. [71]
  J. Mo, L. Deng, K. Peng, et al., J. Hematol. Oncol. 16 (2023) 15.
72. [72]
  L. Pan, X. Chen, F.V. Rassool, C. Li, J. Lin, Biomedicines 10 (2022) 2003. doi: 10.3390/biomedicines10082003
73. [73]
  X. Chen, L. Pan, J. Wei, et al., Sci. Rep. 11 (2021) 6517.
74. [74]
  R. Zhang, X. Yang, D.M. Roque, C. Li, J. Lin, PLoS One 16 (2021) e0240145. doi: 10.1371/journal.pone.0240145
75. [75]
  X. Wang, Y. Lu, D. Sun, et al., Bioorg. Chem. 125 (2022) 105864.
76. [76]
  T. Bekaii-Saab, B. El-Rayes, Cancer 123 (2017) 1303–1312. doi: 10.1002/cncr.30538
77. [77]
  M.A. Shah, K. Shitara, F. Lordick, et al., Clin. Cancer Res. 28 (2022) 3686–3694. doi: 10.1158/1078-0432.ccr-21-4021
78. [78]
  H. Li, M. Cai, F. Cao, et al., Bioorg. Med. Chem. 71 (2022) 116941.
79. [79]
  C. Zhang, L. Yang, X. Yang, et al., Bioorg. Chem. 136 (2023) 106541.
80. [80]
  Y. Chen, H. Xu, L. Chen, et al., New J. Chem. 47 (2023) 156–166. doi: 10.1039/d2nj05206g
81. [81]
  R. Huang, X. Jing, X. Huang, et al., J. Med. Chem. 63 (2020) 1544–1563. doi: 10.1021/acs.jmedchem.9b01386
82. [82]
  M. Yamashita, Y. Nakamori, A. Tsukamoto, N. Furuno, A. Iida, Bioorg. Med. Chem. 90 (2023) 117331. doi: 10.1016/j.bmc.2023.117331
83. [83]
  L. Zhang, P. Liu, Y. Jiang, et al., Eur. J. Med. Chem. 272 (2024) 116448.
84. [84]
  D. Fan, P. Liu, Z. Li, et al., Bioorg. Chem. 150 (2024) 107565.
85. [85]
  P. He, Y. Miao, Y. Sun, et al., J. Med. Chem. 65 (2022) 12650–12674. doi: 10.1021/acs.jmedchem.2c00413
86. [86]
  P. He, A. Bian, Y. Miao, et al., J. Med. Chem. 65 (2022) 15487–15511. doi: 10.1021/acs.jmedchem.2c01554
87. [87]
  Y. Wang, W. Zhou, J. Chen, et al., MedComm 4 (2023) e284. doi: 10.1002/mco2.284
88. [88]
  S. Ouyang, H. Li, L. Lou, et al., Redox Biol. 52 (2022) 102317. doi: 10.1016/j.redox.2022.102317
89. [89]
  H. Li, S. Ouyang, Y. Zhang, et al., Eur. J. Med. Chem. 244 (2022) 114858.
90. [90]
  R. Wang, T. Du, W. Liu, et al., J. Med. Chem. 66 (2023) 12373–12395. doi: 10.1021/acs.jmedchem.3c00863
91. [91]
  A. Turky, A.H. Bayoumi, F.F. Sherbiny, K. El-Adl, H.S. Abulkhair, Mol. Divers. 25 (2020) 403–420.
92. [92]
  S.M. Fawzy, Y.M. Loksha, M. El-Sadek, et al., Arch. Pharm. 356 (2023) e2300345. doi: 10.1002/ardp.202300345
93. [93]
  S. Ma, L. Zhu, X. Fan, et al., Eur. J. Med. Chem. 211 (2021) 113027.
94. [94]
  X. Fan, J. Li, L. Long, et al., Eur. J. Med. Chem. 222 (2021) 113564.
95. [95]
  Y. Zhao, Y. Peng, X. Wei, et al., ACS Chem. Neurosci. 15 (2024) 2484–2503. doi: 10.1021/acschemneuro.4c00060
96. [96]
  W.S. Byun, H. Lim, J. Hong, et al., J. Med. Chem. 66 (2023) 3106–3133. doi: 10.1021/acs.jmedchem.2c01115
97. [97]
  D.H. Jo, S. Lee, E. Bak, et al., Mol. Pharmacol. 100 (2021) 63–72. doi: 10.1124/molpharm.120.000231
98. [98]
  H.J. Jang, S.M. Kim, M.C. Rho, S.W. Lee, Y.H. Song, J. Microbiol. Biotechnol. 29 (2019) 856–862. doi: 10.4014/jmb.1811.11046
99. [99]
  J.Q. Zhang, R. Li, X.Y. Dong, et al., Int. J. Mol. Sci. 23 (2022) 2199. doi: 10.3390/ijms23042199
100. [100]
  W. Jin, T. Zhang, W. Zhou, et al., J. Med. Chem. 65 (2022) 6710–6728. doi: 10.1021/acs.jmedchem.2c00004
101. [101]
  H. Chen, W. Zhou, A. Bian, et al., Clin. Cancer Res. 29 (2023) 815–830. doi: 10.1158/1078-0432.ccr-22-0997
102. [102]
  J. Xu, H. Kim, J. Dong, et al., Eur. J. Med. Chem. 234 (2022) 114229.
103. [103]
  H. Chen, A. Bian, L. Yang, et al., Oncogene 40 (2021) 1440–1457. doi: 10.1038/s41388-020-01626-z
104. [104]
  Y. Wang, C. Yang, M.M. Sims, et al., Cancer Lett. 533 (2022) 215614.
105. [105]
  Z. Yang, H. Xu, Y. Yang, et al., Breast Cancer Res. Treat. 197 (2022) 255–267.
106. [106]
  S. Xu, R. Fan, L. Wang, et al., J. Enzyme Inhib. Med. Chem. 37 (2021) 236–251. doi: 10.1080/14756366.2021.2001805
107. [107]
  N. Wei, J. Burnett, D.L. Crocker, et al., Biochem. Pharmacol. 212 (2023) 115564.
108. [108]
  Y. Zhou, N. He, Q. Liu, et al., J. Med. Chem. 67 (2024) 10783–10794. doi: 10.1021/acs.jmedchem.4c00278
109. [109]
  X. Qi, M. Li, X. Zhang, et al., Molecules 25 (2020) 2306. doi: 10.3390/molecules25102306
110. [110]
  J. Du, L. Jiang, F. Chen, H. Hu, M. Zhou, Front. Oncol. 11 (2021) 684316.
111. [111]
  Y. Shen, H. Cai, S. Ma, et al., J. Nat. Prod. 85 (2022) 765–775.
112. [112]
  X. Guan, J. Yang, W. Wang, et al., Pharmacol. Res. 189 (2023) 106703. doi: 10.1016/j.phrs.2023.106703
113. [113]
  Z. Lü, X. Li, K. Li, et al., ACS Med. Chem. Lett. 12 (2021) 696–703. doi: 10.1021/acsmedchemlett.0c00544
114. [114]
  J. Groot, M. Ott, J. Wei, et al., CNS Oncol. 11 (2022) CNS87.
115. [115]
  B. Wu, S. Fathi, S. Mortley, et al., Bioorg. Med. Chem. 28 (2020) 115345. doi: 10.1016/j.bmc.2020.115345
116. [116]
  B. Wu, B. Payero, S. Taylor, A.K. Oyelere, Future Med. Chem. 13 (2021) 1253–1269. doi: 10.4155/fmc-2021-0088
117. [117]
  X. Shen, L. Zhao, P. Chen, et al., J. Biol. Chem. 294 (2019) 17471–17486. doi: 10.1074/jbc.ra119.009801
118. [118]
  T. Koseki, N. Suehiro, Y. Masuda, et al., Biol. Pharm. Bull. 42 (2019) 792–800. doi: 10.1248/bpb.b18-00992
119. [119]
  P.A. Bonilla, C.L. Hoop, K. Stefanisko, et al., Front. Oncol. 13 (2023) 1144153. doi: 10.3389/fonc.2023.1144153
120. [120]
  L.N. Heppler, D.A. Frank, Cancer Cell 36 (2019) 459–461. doi: 10.1016/j.ccell.2019.10.010
121. [121]
  Y. Yang, H. Xie, X. Yu, et al., Chin. Chem. Lett. 35 (2024) 109570.
122. [122]
  C. Pu, S. Wang, L. Liu, et al., Chin. Chem. Lett. 34 (2023) 107927.
123. [123]
  H. Zhou, L. Bai, R. Xu, et al., J. Med. Chem. 62 (2019) 11280–11300. doi: 10.1021/acs.jmedchem.9b01530
124. [124]
  L. Bai, H. Zhou, R. Xu, et al., Cancer Cell 36 (2019) 498–511. e417.
125. [125]
  H. Zhou, L. Bai, R. Xu, et al., ACS Med. Chem. Lett. 12 (2021) 996–1004. doi: 10.1021/acsmedchemlett.1c00155
126. [126]
  A. Starodub, A. Gollerkeri, C.D. savi, et al., J. Clin. Oncol. 40 (2022) TPS3171. doi: 10.1200/jco.2022.40.16_suppl.tps3171
127. [127]
  J. Jin, Y. Wu, Z. Zhao, et al., JCI Insight 7 (2022) e160606. doi: 10.1172/jci.insight.160606
128. [128]
  H. Li, L. Wang, F. Cao, et al., Front. Pharmacol. 13 (2022) 944455. doi: 10.3389/fphar.2022.944455
129. [129]
  M. Hanafi, X. Chen, N. Neamati, J. Med. Chem. 64 (2021) 1626–1648. doi: 10.1021/acs.jmedchem.0c01897
130. [130]
  C. Zhang, Y. Liu, G. Li, et al., Sci. Bull. 69 (2024) 1776–1797. doi: 10.1016/j.scib.2024.03.056
131. [131]
  S. Ha, J. Zhu, H. Xiang, G. Luo, Chin. Chem. Lett. 35 (2024) 109192. doi: 10.1016/j.cclet.2023.109192
132. [132]
  M. Guo, Y. Song, J. Cheng, et al., Chin. Chem. Lett. 35 (2024) 109392.
133. [133]
  X. Wang, Y. Zhao, X. Li, et al., Nano Lett. 24 (2024) 4858–4868.
134. [134]
  J. Hall, Z. Zhang, S. Bhattacharya, et al., Mol. Ther. Nucleic Acids 35 (2024) 102137.
135. [135]
  P. Shih, Life Sci. 242 (2020) 117241.
136. [136]
  Y. Sun, X. Luo, Z. Yang, et al., Chin. Chem. Lett. 34 (2023) 107924.
1. [1]
  Zimo Yang , Yan Tong , Yongbo Liu , Qianlong Liu , Zhihao Ni , Yuna He , Yu Rao . Developing selective PI3K degraders to modulate both kinase and non-kinase functions. Chinese Chemical Letters, 2024, 35(11): 109577-. doi: 10.1016/j.cclet.2024.109577
2. [2]
  Shengyi Gong , Guoqiang Feng . Visible light-triggered NIR ratiometric fluorescent metal-free CO-releasing molecule for self-monitoring of CO delivery and effective cancer therapy. Chinese Chemical Letters, 2025, 36(7): 110409-. doi: 10.1016/j.cclet.2024.110409
3. [3]
  Keliang Li , Guoqiang Dong , Shanchao Wu , Chunquan Sheng . Discovery of an activatable near-infrared fluorescent and theranostic PROTAC for tumor-targeted detecting and degrading of BRD4. Chinese Chemical Letters, 2025, 36(6): 110280-. doi: 10.1016/j.cclet.2024.110280
4. [4]
  Yuanyi Zhou , Ke Ma , Jinfeng Liu , Zirun Zheng , Bo Hu , Yu Meng , Zhizhong Li , Mingshan Zhu . Is reactive oxygen species the only way for cancer inhibition over single atom nanomedicine? Autophagy regulation also works. Chinese Chemical Letters, 2024, 35(6): 109056-. doi: 10.1016/j.cclet.2023.109056
5. [5]
  Yuanyuan Zeng , Fang Liu , Jun Wang , Bianfei Shao , Tao He , Zhongzheng Xiang , Yan Wang , Shunyao Zhu , Tian Yang , Siting Yu , Changyang Gong , Lei Liu . Fisetin micelles precisely exhibit a radiosensitization effect by inhibiting PDGFRβ/STAT1/STAT3/Bcl-2 signaling pathway in tumor. Chinese Chemical Letters, 2025, 36(2): 109734-. doi: 10.1016/j.cclet.2024.109734
6. [6]
  Yueying Yang , Huiru Xie , Xinbo Yu , Yang Liu , Hui Wang , Hua Li , Lixia Chen . Design, synthesis and evaluation of the first DYRK1A degrader for promoting the proliferation of pancreatic β-cells. Chinese Chemical Letters, 2024, 35(11): 109570-. doi: 10.1016/j.cclet.2024.109570
7. [7]
  Ziqin Li , Kai Hao , Longwei Xiang , Huayu Tian . Cationic covalent organic framework nanocarriers integrating both efficient gene silencing and real-time gene detection. Chinese Chemical Letters, 2025, 36(4): 109943-. doi: 10.1016/j.cclet.2024.109943
8. [8]
  Yixin Sun , Keke Yu , Xiuchun Guo , Lanlan Zong , Zhonggui He , Xiaohui Pu . Three-in-one reduction and acid-ignited micelles amplify antitumor efficacy via precise synergistic delivery of paclitaxel and naringenin. Chinese Chemical Letters, 2025, 36(6): 110393-. doi: 10.1016/j.cclet.2024.110393
9. [9]
  Qinyu Zhao , Yunchao Zhao , Songjing Zhong , Zhaoyang Yue , Zhuoheng Jiang , Shaobo Wang , Quanhong Hu , Shuncheng Yao , Kaikai Wen , Linlin Li . Urchin-like piezoelectric ZnSnO₃/Cu₃P p-n heterojunction for enhanced cancer sonodynamic therapy. Chinese Chemical Letters, 2024, 35(12): 109644-. doi: 10.1016/j.cclet.2024.109644
10. [10]
  Ali Dai , Zhiguo Zheng , Liusheng Duan , Jian Wu , Weiming Tan . Small molecule chemical scaffolds in plant growth regulators for the development of agrochemicals. Chinese Chemical Letters, 2025, 36(4): 110462-. doi: 10.1016/j.cclet.2024.110462
11. [11]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
12. [12]
  Mengjuan Sun , Muye Zhou , Yifang Xiao , Hailei Tang , Jinhua Chen , Ruitao Zhang , Chunjiayu Li , Qi Ya , Qian Chen , Jiasheng Tu , Qiyue Wang , Chunmeng Sun . Reversibly size-switchable polyion complex micelles for antiangiogenic cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109110-. doi: 10.1016/j.cclet.2023.109110
13. [13]
  Xiaofang Luo , Ye Wu , Xiaokun Zhang , Min Tang , Feiye Ju , Zuodong Qin , Gregory J Duns , Wei-Dong Zhang , Jiang-Jiang Qin , Xin Luan . Peptide-based strategies for overcoming multidrug-resistance in cancer therapy. Chinese Chemical Letters, 2025, 36(1): 109724-. doi: 10.1016/j.cclet.2024.109724
14. [14]
  Han Yuan , Fengcai Zhang , Hongzhe Huang , Jiafei Wu , Yi Yang , Wanyi Huang , Dongjing Yang , Zhuoming Li , Zhe Li , Ling Huang , Yi-You Huang , Hai-Bin Luo , Lei Guo . Discovery of 3-trifluoromethyl-substituted pyrazoles as selective phosphodiesterase 10A inhibitors for orally attenuating isoprenaline-induced cardiac hypertrophy. Chinese Chemical Letters, 2025, 36(4): 109965-. doi: 10.1016/j.cclet.2024.109965
15. [15]
  Zhi Li , Shuya Pan , Yuan Tian , Shaowei Liu , Weifeng Wei , Jinlin Wang , Tianfeng Chen , Ling Wang . Selenium nanoparticles enhance the chemotherapeutic efficacy of pemetrexed against non-small cell lung cancer. Chinese Chemical Letters, 2024, 35(12): 110018-. doi: 10.1016/j.cclet.2024.110018
16. [16]
  Bohao Liu , Xue Jiang , Ruizhi Ning , Heng Zhao , Yanpeng Zhang , Junnan Zhang , Tianqing Liu , Danyao Qu , Yinhui Bao , Zhanchen Guo , Xiaoyan Zeng , Shan Gao , Kun Fan , Runyi Tao , Jian Ji , Guangjian Zhang , Weiwei Wu . Tedlar bag free: Accurate volatolomics of ⅠA stage non-small cell lung cancer come out in wash. Chinese Chemical Letters, 2025, 36(6): 110301-. doi: 10.1016/j.cclet.2024.110301
17. [17]
  Kun Zhang , Ni Dan , Dan-Dan Ren , Ruo-Yu Zhang , Xiaoyan Lu , Ya-Pan Wu , Li-Lei Zhang , Hong-Ru Fu , Dong-Sheng Li . A small D-A molecule with highly heat-resisting room temperature phosphorescence for white emission and anti-counterfeiting. Chinese Journal of Structural Chemistry, 2024, 43(3): 100244-100244. doi: 10.1016/j.cjsc.2024.100244
18. [18]
  Aolei Tan , Xiaoxiao Ma . Exploring the functional roles of small-molecule metabolites in disease research: Recent advancements in metabolomics. Chinese Chemical Letters, 2024, 35(8): 109276-. doi: 10.1016/j.cclet.2023.109276
19. [19]
  Hyoseok Kim , Changyi Cui , Kohei Toh , Genyir Ado , Tetsuya Ogawa , Yixin Zhang , Shin-ichi Sato , Yong-Beom Lim , Hiroki Kurata , Lu Zhou , Motonari Uesugi . Discovery of a self-assembling small molecule that sequesters RNA-binding proteins. Chinese Chemical Letters, 2025, 36(5): 110135-. doi: 10.1016/j.cclet.2024.110135
20. [20]
  Wen Su , Siying Liu , Qingfu Zhang , Zhongyan Zhou , Na Wang , Lei Yue . Temperature-controlled electrospray ionization tandem mass spectrometry study on protein/small molecule interaction. Chinese Chemical Letters, 2025, 36(5): 110237-. doi: 10.1016/j.cclet.2024.110237

Get Citation

PDF

XML

Metrics

PDF Downloads(0)
Abstract views(5)
HTML views(1)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142